Fragmento

Doxonrubicin is an antineoplastic agent with a broad spectrum of activity in both the adult an pediatric population. It demostrates activity against both hematologic ans solid tumors, and many regimens employed as first or second-line therapies in pediatric patients include doxurubicin or one of several closely related anthracycline or other anthraquinones. Unfortunatelye, doxorubicin and related agents are associated with a cumulative dose-related clinically severe congestive heart failure and death. The mechanism of cardiac damage is complex and not fully understood.

Palabras clave:

2004-09-08   |   927 visitas   |   Evalua este artículo 0 valoraciones

Vol. 17 Núm.5. Septiembre-Octubre 1996 Pags. 260-263 Acta Pediatr Méx 1996; 17(5)